Long-term statin use and the risk of Parkinson's disease

American Journal of Managed Care

Volumn 19, Issue 8, 2013, Pages 626-632

  Friedman, Bitya ^a,b   Lahad, Amnon ^c,d   Dresner, Yizchak ^d,e   Vinker, Shlomo ^d,e  

^a HERZOG HOSPITAL   (Israel)

^b HEBREW UNIVERSITY   (Israel)

^c Departmentof Family Medicine   (Israel)

^d CLALIT HEALTH SERVICES   (Israel)

^e TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMAN; HYPERTENSION; INCIDENCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; SEX DIFFERENCE; SMOKING; SOCIAL STATUS; TREATMENT DURATION;

CHOLESTEROL, LDL; COHORT STUDIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; ISRAEL; MALE; MIDDLE AGED; PARKINSON DISEASE;

EID: 84883790561     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations. 2005 through 2030. Neurology. 2007;68(5):384-386. (Pubitemid 46184217)
2. Xu Q, Park Y, Huang X, et al. Diabetes and risk of Parkinson's disease. Diabetes Care. 2011;34(4):910-915.
3. Hu G, Jousilahti P, Bidel S, Antikainen R, Tuomilehto J. Type 2 diabetes and the risk of Parkinson's disease. Diabetes Care. 2007;30(4): 842-847. (Pubitemid 46562366)
4. Hu G, Jousilahti P, Nissinen A, Antikainen R, Kivipelto M, Tuomilehto J. Body mass index and the risk of Parkinson disease. Neurology. 2006;67(11):1955-1999.
5. Logroscino G, Sesso HD, Paffenbarger RS Jr, Lee IM. Body mass index and risk of Parkinson's disease: a prospective cohort study. Am J Epidemiol. 2007;166(10):1186-1190. (Pubitemid 350022758)
6. Qiu C, Hu G, Kivipelto M, et al. Association of blood pressure and hypertension with the risk of parkinson disease: the National FINRISK/Study. Hypertension. 2011;57(6):1094-1100.
7. Ritz B, Ascherio A, Checkoway H, et al. Pooled analysis of tobacco use and risk of Parkinson disease. Arch Neurol. 2007;64(7):990-997. (Pubitemid 47047999)
8. Thacker EL, O'Reilly EJ, Weisskopf MG, et al. Temporal relationship between cigarette smoking and risk of Parkinson disease. Neurology. 2007;68(10):764-768. (Pubitemid 46667902)
9. Huang X, Chen H, Miller WC, et al. Lower low-density lipoprotein cholesterol levels are associated with Parkinson's disease. Mov Disord. 2007;22(3):377-381. (Pubitemid 46569693)
10. de Lau LM, Koudstaal PJ, Hofman A, Breteler MM. Serum cholesterol levels and the risk of Parkinson's disease. Am J Epidemiol. 2006; 164(10):998-1002. (Pubitemid 44729842)
11. Huang X, Abbott RD, Petrovitch H, Mailman RB, Ross W. Low LDL cholesterol and increased risk of Parkinson's disease: prospective results from Honolulu-Asia Aging Study. Mov Disord. 2008;23(7):1013-1038.
12. Wahner AD, Bronstein JM, Bordelon YM, Ritz B. Statin use and the risk of Parkinson disease. Neurology. 2008;70(16, pt 2):1418-1422. (Pubitemid 351521934)
13. Ritz B, Manthripragada AD, Qian L, et al. Statin use and Parkinson's disease in Denmark. Mov Disord. 2010;25(9):1210-1216.
14. Simon KC, Chen H, Schwarzschild M, Ascherio A. Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease. Neurology. 2007;69(17):1688-1695. (Pubitemid 350287125)
15. Gao X, Simon KC, Schwarzschild MA, Ascherio A. Prospective study of statin use and risk of Parkinson disease. Arch Neurol. 2012;69(3): 380-384.
16. Samii A, Carleton BC, Etminan M. Statin use and the risk of Parkinson disease: a nested case control study. J Clin Neurosci. 2008;15(11): 1272-1273.
17. Armitage J. The safety of statins in clinical practice. Lancet. 2007; 370(9601):1781.
18. Ward S, Lloyd Jones M, Pandor A, et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess. 2007;11(14):1-160.
19. Roy A, Pahan K. Prospects of statins in Parkinson disease. Neuroscientist. 2011;17(3):244-255.
20. Ghosh A, Roy A, Matras J, Brahmachari S, Gendelman HE, Pahan K. Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease. J Neurosci. 2009;29(43):13543-13556.
21. Bar-On P, Crews L, Koob AO, et al. Statins reduce neuronal alphasynuclein aggregation in in vitro models of Parkinson's disease. J Neurochem. 2008;105(5):1656-1667. (Pubitemid 351678486)
22. Lieberman A, Lyons K, Levine J, Myerburg R. Statins, cholesterol, co-enzyme Q10, and Parkinson's disease. Parkinsonism Relat Disord. 2005;11(2):81-84. (Pubitemid 40279146)
23. Mancuso M, Orsucci D, Volpi L, Calsolaro V, Siciliano G. Coenzyme Q10 in neuromuscular and neurodegenerative disorders. Curr Drug Targets. 2010;11(1):111-121.
24. Huang X, Chen PC, Poole C. APOE-[epsilon]2 allele associated with higher prevalence of sporadic Parkinson disease. Neurology. 2004; 62(12):2198-2202. (Pubitemid 38787775)
25. Wilson PW, Myers RH, Larson MG, Ordovas JM, Wolf PA, Schaefer EJ. Apolipoprotein E alleles, dyslipidemia, and coronary heart disease: the Framingham Offspring Study. JAMA 1994;272(21):1666-1671. (Pubitemid 24359137)
26. Hu G, Antikainen R, Jousilahti P, Kivipelto M, Tuomilehto J. Total cholesterol and the risk of Parkinson disease. Neurology. 2008;70(21): 1972-1979.
27. Rennert G, Peterburg Y. Prevalence of selected chronic diseases in Israel. Isr Med Assoc J. 2001;3(6):404-408. (Pubitemid 34176916)
28. Tabenkin, H. Clinical guidelines: Israeli task-force recommendations for health promotion and preventive health services. http://www.ima.org.il/Ima/ FormStorage/Type1/clinical-09-preventive.pdf. Published 2008. Accessed January 2009.
29. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-3421.
30. Rao SR, Schoenfeld DA. Survival methods. Circulation. 2007;115(1): 109-113. (Pubitemid 46058618)
31. Orr JD. Statins in the spectrum of neurologic disease. Curr Atheroscler Rep. 2008;10(1):11-18. (Pubitemid 351385594)
32. Thanvi B, Lo N, Robinson T. Vascular parkinsonism-an important cause of parkinsonism in older people. Age Ageing. 2005;34(2):114-119. (Pubitemid 40331090)
33. Rektor I, Rektorová I, Kubová D. Vascular parkinsonism-an update. J Neurol Sci. 2006;248(1-2):185-191.
34. Elbaz A, Moisan F. Update in the epidemiology of Parkinson's disease. Curr Opin Neurol. 2008;21(4):454-460.
35. Lees AJ, Hardy J, Revesz T. Parkinson's disease [published correction appears in Lancet. 2009;374(9691):684]. Lancet. 2009;373(9680): 2055-2066.
36. Shulman LM, Bhat V. Gender disparities in Parkinson's disease. Expert Rev Neurother. 2006;6(3):407-416.